Literature DB >> 32300244

Exogenous pancreatic kininogenase protects against renal fibrosis in rat model of unilateral ureteral obstruction.

Ji-Zhe Jin1, Hui-Ying Li1,2, Jian Jin1, Shang-Guo Piao1, Xiong-Hu Shen3, Yan-Ling Wu4, Jia-Chong Xu5, Long-Ye Zhang1, Yu-Ji Jiang1, Hai-Lan Zheng1, Ying-Shun Jin1, Sheng Cui1, Kang Luo1, Yi Quan1, Can Li6.   

Abstract

Tissue kallikrein has protective function against various types of injury. In this study, we investigated whether exogenous pancreatic kininogenase (PK) conferred renoprotection in a rat model of unilateral ureteral obstruction (UUO) and H2O2-treated HK-2 cells in vitro. SD rats were subjected to UUO surgery, then PK (7.2 U/g per day, ip) was administered for 7 or 14 days. After the treatment, rats were euthanized; the obstructed kidneys were harvested for further examination. We found that PK administration significantly attenuated interstitial inflammation and fibrosis, and downregulated the expression of proinflammatory (MCP-1, TLR-2, and OPN) and profibrotic (TGF-β1 and CTGF) cytokines in obstructed kidney. UUO-induced oxidative stress, closely associated with excessive apoptotic cell death and autophagy via PI3K/AKT/FoxO1a signaling, which were abolished by PK administration. We further showed that PK administration increased the expression of bradykinin receptors 1 and 2 (B1R and B2R) mRNA and the production of NO and cAMP in kidney tissues. Coadministration with either B1R antagonist (des-Arg9-[Leu8]-bradykinin) or B2R antagonist (icatibant) abrogated the renoprotective effects of PK, and reduced the levels of NO and cAMP in obstructed kidney. In H2O2-treated HK-2 cells, addition of PK (6 pg/mL) significantly decreased ROS production, regulated the expression of oxidant and antioxidant enzymes, suppressed the expression of TGF-β1 and MCP-1, and inhibited cell apoptosis. Our data demonstrate that PK treatment protects against the progression of renal fibrosis in obstructed kidneys.

Entities:  

Keywords:  apoptosis; autophagy; kallikrein; oxidative stress; renal fibrosis

Year:  2020        PMID: 32300244      PMCID: PMC7921586          DOI: 10.1038/s41401-020-0393-7

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  43 in total

Review 1.  The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction.

Authors:  Julie Chao; Grant Bledsoe; Hang Yin; Lee Chao
Journal:  Biol Chem       Date:  2006-06       Impact factor: 3.915

Review 2.  Chronic kidney disease.

Authors:  Paola Romagnani; Giuseppe Remuzzi; Richard Glassock; Adeera Levin; Kitty J Jager; Marcello Tonelli; Ziad Massy; Christoph Wanner; Hans-Joachim Anders
Journal:  Nat Rev Dis Primers       Date:  2017-11-23       Impact factor: 52.329

3.  Lipoxin A₄ and benzo-lipoxin A₄ attenuate experimental renal fibrosis.

Authors:  Emma Börgeson; Neil G Docherty; Madeline Murphy; Karen Rodgers; Aidan Ryan; Tim P O'Sullivan; Patrick J Guiry; Roel Goldschmeding; Debra F Higgins; Catherine Godson
Journal:  FASEB J       Date:  2011-05-31       Impact factor: 5.191

4.  Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats.

Authors:  David Montanari; Hang Yin; Eric Dobrzynski; Jun Agata; Hideaki Yoshida; Julie Chao; Lee Chao
Journal:  Diabetes       Date:  2005-05       Impact factor: 9.461

5.  Selective inhibition of class IIa histone deacetylases alleviates renal fibrosis.

Authors:  Chongxiang Xiong; Yingjie Guan; Xiaoxu Zhou; Lirong Liu; Michelle A Zhuang; Wei Zhang; Yunhe Zhang; Monica V Masucci; George Bayliss; Ting C Zhao; Shougang Zhuang
Journal:  FASEB J       Date:  2019-04-05       Impact factor: 5.191

6.  Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat.

Authors:  Claude Braun; Thomas Kleemann; Ulrich Hilgenfeldt; Udo Riester; Peter Rohmeiss; Fokko J van der Woude
Journal:  Kidney Int       Date:  2002-06       Impact factor: 10.612

7.  Kallikrein protects against microalbuminuria in experimental type I diabetes.

Authors:  Sophie Bodin; Catherine Chollet; Nicolas Goncalves-Mendes; Joelle Gardes; Franck Pean; Didier Heudes; Patrick Bruneval; Michel Marre; François Alhenc-Gelas; Nadine Bouby
Journal:  Kidney Int       Date:  2009-06-10       Impact factor: 10.612

8.  Exogenous kallikrein protects against diabetic nephropathy.

Authors:  Wenjuan Liu; Yeping Yang; Yemei Liu; Xiaolan Lu; Shizhe Guo; Meng Wu; Meng Wang; Linling Yan; Qinghua Wang; Xiaolong Zhao; Xian Tong; Ji Hu; Yiming Li; Renming Hu; Robert C Stanton; Zhaoyun Zhang
Journal:  Kidney Int       Date:  2016-08-18       Impact factor: 10.612

9.  The protective activity of noscapine on renal ischemia-reperfusion injury in male Wistar rat.

Authors:  Mehrangiz Khanmoradi; Seyyed Ali Mard; Nahid Aboutaleb; Malihe Nobakht; Masoud Mahmoudian
Journal:  Iran J Basic Med Sci       Date:  2014       Impact factor: 2.699

Review 10.  Protective Role of Endogenous Kallistatin in Vascular Injury and Senescence by Inhibiting Oxidative Stress and Inflammation.

Authors:  Julie Chao; Youming Guo; Lee Chao
Journal:  Oxid Med Cell Longev       Date:  2018-12-02       Impact factor: 6.543

View more
  6 in total

1.  Reactive oxygen species induced by uric acid promote NRK‑52E cell apoptosis through the NEK7‑NLRP3 signaling pathway.

Authors:  Dongdong Li; Luobing Wang; Jiaoying Ou; Chuanxu Wang; Jiabao Zhou; Lili Lu; Yanshneg Wu; Jiandong Gao
Journal:  Mol Med Rep       Date:  2021-08-20       Impact factor: 2.952

2.  Effects of L-carnitine combined with pancreatic kininogenase on thioredoxin 2, thioredoxin reductase 1, and sperm quality in patients with oligoasthenospermia.

Authors:  Yang Wang; Rui Zhang; Weijun Pan; Zhe Xu; Huan Yang; Qi Luo; Xiping Ye; Xianfeng Cheng
Journal:  Transl Androl Urol       Date:  2021-08

3.  Bradykinin-mediated estrogen-dependent depressor response by direct activation of female-specific distribution of myelinated Ah-type baroreceptor neurons in rats.

Authors:  Ke-Xin Li; Yan Feng; Xiong-Xiong Fan; Xun Sun; Ying Li; Di Wu; Li Liu; Chang-Peng Cui; Xue Xiong; Hu-Die Li; Meng Zhou; Hai-Lan Ma; Yang Liu; Rong Zhang; Bai-Yan Li
Journal:  CNS Neurosci Ther       Date:  2021-12-28       Impact factor: 5.243

4.  Inhibition of RIP1-RIP3-mediated necroptosis attenuates renal fibrosis via Wnt3α/β-catenin/GSK-3β signaling in unilateral ureteral obstruction.

Authors:  Shang Guo Piao; Jun Ding; Xue Jing Lin; Qi Yan Nan; Mei Ying Xuan; Yu Ji Jiang; Hai Lan Zheng; Ji Zhe Jin; Can Li
Journal:  PLoS One       Date:  2022-10-12       Impact factor: 3.752

5.  Dapagliflozin Alleviates Renal Fibrosis by Inhibiting RIP1-RIP3-MLKL-Mediated Necroinflammation in Unilateral Ureteral Obstruction.

Authors:  Mei Ying Xuan; Shang Guo Piao; Jun Ding; Qi Yan Nan; Mei Hua Piao; Yu Ji Jiang; Hai Lan Zheng; Ji Zhe Jin; Can Li
Journal:  Front Pharmacol       Date:  2022-01-07       Impact factor: 5.810

6.  Ephedrine alleviates middle cerebral artery occlusion-induced neurological deficits and hippocampal neuronal damage in rats by activating PI3K/AKT signaling pathway.

Authors:  Lixian Huang; Bo Zhao; Qunxian Li; Jing Wu; Hui Jiang; Qingbin Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.